SDZNY vs. STVN: Which Stock Offers Better Value?

Written by Emily J. Thompson, Senior Investment Analyst

Source: NASDAQ.COM

Updated: Dec 19 2025

0mins

STVN+9.54%

Should l Buy STVN?

Source: NASDAQ.COM

Stock Comparison: Sandoz Group AG Sponsored ADR (SDZNY) has a Zacks Rank of #2 (Buy) indicating a strong earnings outlook, while Stevanato Group (STVN) has a Zacks Rank of #3 (Hold), suggesting a weaker position.
Valuation Metrics: SDZNY shows a forward P/E ratio of 22.38 and a PEG ratio of 1.20, indicating better value compared to STVN's forward P/E of 34.66 and PEG ratio of 2.03.
Value Grades: Based on various valuation metrics, SDZNY holds a Value grade of B, while STVN has a Value grade of C, further supporting SDZNY as the superior value option.
Investment Recommendations: Zacks Investment Research highlights SDZNY as a strong investment opportunity, alongside other top stock recommendations with potential for significant returns.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy STVN?" and start using high-conviction signals backed by rigorous historical data.

STVN

$15.5+Infinity%1D

Analyst Views on STVN

Wall Street analysts forecast STVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STVN is 27.00 USD with a low forecast of 24.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Analyst Rating

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 14.150

Low

24.00

Averages

27.00

High

30.00

Current: 14.150

Low

24.00

Averages

27.00

High

30.00

KeyBanc

maintain

$200 basis points

2025-12-24

Reason

KeyBanc

Price Target

$200 basis points

AI Analysis

2025-12-24

maintain

Reason

KeyBanc believes the risk to oral weight loss drugs remains limited to 2030 from the approval of Wegovy's oral version. Oral GLP-1 market penetration will remain capped in the near and long term despite new market approvals, the analyst tells investors in a research note. KeyBanc believes the oral version of Wegovy will only contribute 200 basis points to overall GLP-1 market share by 2030. The firm thinks GLP-1 suppliers are likely conservative with their market assumptions. West Pharmaceutical (WST) and Stevanato Group (STVN) have both commented on their market assumption that orals will have 30% market share of the overall GLP-1 market, it notes. KeyBanc expects both suppliers to continue to ramp as the market launches next-generation GLP-1s in injectable format.

Morgan Stanley

Tejas Savant

Equal Weight

maintain

$24 -> $26

2025-11-11

Reason

Morgan Stanley

Tejas Savant

Price Target

$24 -> $26

2025-11-11

maintain

Equal Weight

Reason

Morgan Stanley analyst Tejas Savant raised the firm's price target on Stevanato Group to $26 from $24 and keeps an Equal Weight rating on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for STVN

Unlock Now

About STVN

Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

S&P 500 Index Edges Up as Tech Stocks Rally

Jan 24 2026NASDAQ.COM

Tech Stock Rally: The S&P 500 Index rose by 0.03% driven by a rebound in the Magnificent Seven tech stocks, indicating a recovery in market confidence despite ongoing uncertainties.
Consumer Confidence Boost: The University of Michigan's consumer sentiment index was revised up to 56.4, a five-month high, exceeding expectations of 54.0, suggesting increased consumer confidence that could stimulate spending.
Easing Inflation Expectations: The one-year inflation expectations were revised down from 4.2% to 4.0%, reflecting a reduction in market concerns about future inflation, which may support stock performance.
Oil Price Surge: WTI crude oil prices jumped over 2% to a one-week high as President Trump reiterated military threats against Iran, boosting energy stocks and highlighting the impact of geopolitical risks on the market.

S&P 500 Futures Rise in Pre-Market Session; Venture Global and Karman Holdings Take the Lead

Jan 22 2026Barron's

Market Opening: U.S. stock markets are set to open in two hours.
Venture Global Inc. Performance: Venture Global Inc. (VG) saw a 9.9% increase in pre-market trading.
Karman Holdings Inc. Performance: Karman Holdings Inc. (KRMN) experienced a 9.5% rise in pre-market trading.
Overall Market Sentiment: The pre-market gains indicate positive sentiment ahead of the market opening.

Datwyler Collaborates with LTS and Stevanato to Launch Large-Volume Drug Delivery Solutions

Jan 16 2026PRnewswire

Growing Market Demand: According to Precedence Research, the U.S. biologics market is projected to reach $483 billion by 2034, driving the need for large-volume subcutaneous drug delivery solutions, prompting Datwyler's collaboration with LTS and Stevanato to address market shifts.
Patient Self-Administration Convenience: A Mayo Clinic study found that 73% of participants preferred in-home self-administration, highlighting the urgent demand for convenient patient-centric healthcare solutions, with Datwyler's NeoFlex™ plungers enhancing the reliability and safety of large-volume injection systems.
Technological Innovation Showcase: The three companies will jointly present their platform solution at Pharmapack on January 21-22, 2026, aiming to optimize the development of pre-verified container closure systems, advancing technology for large-volume drug self-administration.
Accelerated Market Access: Through collaboration, the companies will offer a pre-verified ecosystem to expedite market access, meeting stringent safety and efficacy requirements for self-administered therapies of up to 20 mL, further solidifying their market leadership in drug delivery solutions.

Datwyler Collaborates with LTS and Stevanato to Launch Large-Volume Drug Delivery Solutions

Jan 16 2026Newsfilter

Market Demand Response: Datwyler's collaboration with LTS Device Technologies and Stevanato Group introduces large-volume subcutaneous drug delivery solutions, addressing the needs of 73% of patients who prefer in-home self-administration, thus facilitating a shift towards personalized healthcare at home.
Technology Innovation Showcase: The three companies will unveil their pre-verified large-volume drug delivery platform at Pharmapack on January 21-22, 2026, aiming to accelerate market access and enhance patient medication experiences.
Product Functionality Enhancement: Datwyler's NeoFlex™ plungers support drug delivery volumes of up to 20mL, overcoming the limitations of traditional low-volume delivery while ensuring safety and therapeutic efficacy, catering to the rapid growth of the biologics market.
Industry Outlook: The U.S. biologics market is projected to reach $483 billion by 2034, and Datwyler's collaboration will provide innovative solutions for pharmaceutical companies, helping them maintain a competitive edge in a challenging market.